TY  - JOUR
AU  - Pennings, Elise R A
AU  - Thielen, Frederick W
AU  - Broussais, Florence
AU  - Delgado, Julio
AU  - Jaeger, Ulrich
AU  - Sanges, Carmen
AU  - Cabrerizo, Yolanda
AU  - Roux-Opstaele, Lutgart
AU  - Dreuillet, Caroline
AU  - Gonzalez-Marcano, Eglys
AU  - Millán, Olga
AU  - Huber, Barbara
AU  - Clavreul, Solène
AU  - Bolaños, Natacha
AU  - Nier, Samantha
AU  - Mihályová, Jana
AU  - Hájek, Roman
AU  - Horňáková, Michaela
AU  - Doeswijk, Robin
AU  - Thieblemont, Catherine
AU  - Hudecek, Michael
AU  - Uyl-de Groot, Carin A
AU  - Kersten, Marie José
TI  - The European CAR-T map-Current status and future directions to improve access to CAR T-cell therapy for hematologic malignancies.
JO  - HemaSphere
VL  - 10
IS  - 3
SN  - 2572-9241
CY  - Hoboken
PB  - John Wiley & Sons Ltd.
M1  - DKFZ-2026-00560
SP  - e70306
PY  - 2026
N1  - #NCTZFB9#
AB  - Despite its great promise, implementation of CAR-T therapy-a personalized, logistically complex, and expensive treatment-remains challenging, hampering patient access across and within countries. Since 2018, six products have been centrally approved in Europe (i.e., the European Economic Area; EU-approved) for 15 hematologic malignancy indications. To better understand patient access to EU-approved commercial CAR-T therapy, we evaluated the current status in all 30 countries where EU-approval is valid plus the UK, addressing economic, clinical, and organizational aspects, and identifying challenges and strategies for improvement. A two-step approach was used, complementing data from marketing authorization holders (4/4 responded) with country-specific insights from clinical experts obtained via an online survey (30/31 responded). In August 2024, 26
LB  - PUB:(DE-HGF)16
C6  - pmid:41799248
C2  - pmc:PMC12961523
DO  - DOI:10.1002/hem3.70306
UR  - https://inrepo02.dkfz.de/record/310364
ER  -